Stock Groups

Pfizer Earnings, Revenue Beat in Q3 -Breaking

by Mike Robinson

[ad_1]

© Reuters Pfizer Earnings, Revenue Beat in Q3

Investing.com Pfizer (NYSE: ) On Tuesday, the company reported its third quarter results that exceeded analysts’ expectations and generated revenue that was above all estimates.

Pfizer declared earnings per share (EPS) of $1.34 based on $24.09B in revenue. Investing.com polled analyst to predict EPS of $1.08 based on $22.56B in revenue.

Pfizer shares rose 18% over the first of the year but are down 15.85% from August 18, when it hit a 52-week high at $51.86. They are under-performing the S&P Global 100 which is up 19.28% from the start of the year.

Pfizer reports on other earnings in the healthcare sector.

Pfizer’s report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.

Thermo Fisher Scientific beat all expectations with a third quarter EPS at $5.76 on revenues of $9.33B. This compares to a forecast of EPS at $4.68 for revenue of $8.38B.

You can keep up-to date on the latest earnings reports by visiting Investing.com’s earnings calendar

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, futures, indexes and Forex. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for loss or damages resulting from reliance on data including charts, buy/sell signals, and quotes. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]